Business Description
Lexeo Therapeutics Inc
NAICS : 541715
SIC : 2834
ISIN : US52886X1072
Description
Lexeo Therapeutics Inc is a a clinical-stage genetic medicines company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. Its pipeline consists of candidates targeting patient populations that place significant burden on society and are most amenable to their genetic medicine approach. The Company is focused on preclinical and clinical stage gene therapies, and specifically on hereditary and acquired diseases of high unmet need which is their only business segment.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 10.44 | |||||
| Equity-to-Asset | 0.81 | |||||
| Debt-to-Equity | 0.1 | |||||
| Debt-to-EBITDA | -0.25 | |||||
| Piotroski F-Score | 4/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -304.2 | |||||
| 3-Year EPS without NRI Growth Rate | -303 | |||||
| 3-Year FCF Growth Rate | -347.9 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 52.71 | |||||
| 9-Day RSI | 45.42 | |||||
| 14-Day RSI | 43.06 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 7.21 | |||||
| Quick Ratio | 7.21 | |||||
| Cash Ratio | 7.05 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.9 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROA % | -53.55 | |||||
| ROIC % | -220.92 | |||||
| ROC (Joel Greenblatt) % | -368.78 | |||||
| ROCE % | -66.02 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 2.93 | |||||
| Price-to-Tangible-Book | 2.93 | |||||
| EV-to-EBIT | -6.11 | |||||
| EV-to-EBITDA | -6.24 | |||||
| EV-to-FCF | -4.87 | |||||
| Price-to-Net-Current-Asset-Value | 3.4 | |||||
| Price-to-Net-Cash | 3.5 | |||||
| Earnings Yield (Greenblatt) % | -16.37 | |||||
| FCF Yield % | -14.49 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:LXEO
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Lexeo Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.865 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 43.06 | ||
| 14-Day ATR ($) | 0.958771 | ||
| 20-Day SMA ($) | 12.888 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range ($) | 9 - 22.33 | ||
| Shares Outstanding (Mil) | 32.95 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Lexeo Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Lexeo Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Lexeo Therapeutics Inc Frequently Asked Questions
What is Lexeo Therapeutics Inc(LXEO)'s stock price today?
The current price of LXEO is $12.50. The 52 week high of LXEO is $22.33 and 52 week low is $9.00.
When is next earnings date of Lexeo Therapeutics Inc(LXEO)?
The next earnings date of Lexeo Therapeutics Inc(LXEO) is 2024-05-31 Est..
Does Lexeo Therapeutics Inc(LXEO) pay dividends? If so, how much?
Lexeo Therapeutics Inc(LXEO) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers